New diagnostic and imaging tools continue to move toward earlier detection and more precise risk stratification. Photocure’s acquisition of Vesica Health further expands the urine molecular diagnostics footprint by adding AssureMDx, which Photocure said has shown 96% sensitivity and 99.7% negative predictive value in its validation work and has guideline inclusion support. Separately, research highlighted a noninvasive molecular approach for early bladder cancer detection and broader oncology monitoring: Methylation-based ctDNA analysis was reported as tracking metastatic breast cancer therapy response to CDK4/6 inhibitors, pointing to real-time disease dynamics rather than periodic snapshots. Across platforms, the industry momentum is toward assays that can be scaled into routine workflows and correlated with clinically actionable timelines.